Abraham Scaria
Company: IVERIC bio
Job title: Chief Scientific Officer
Bio:
Dr. Scaria has more than 25 years of experience in gene therapy, ranging from discovery research to early-stage clinical trials. For much of his career, Dr. Scaria has specialized in viral gene therapy vectors and ocular gene therapy, having served as Senior Scientific Director of Gene Therapy and Ophthalmology at Genzyme-Sanofi and subsequently Head of Gene Therapy Research at Sanofi. Most recently, Dr. Scaria was Vice President and Head of Ophthalmology at Casebia Therapeutics, where he oversaw efforts to develop gene-editing based therapies for inherited retinal diseases. He earned his doctorate in biochemistry and molecular biology from Indiana University School of Medicine and conducted postdoctoral research at St. Louis University School of Medicine and at the University of Washington School of Medicine in Seattle. Dr. Scaria has more than 45 publications and currently serves on several committees for the American Society for Gene and Cell Therapy.
Seminars:
Chair’s Closing Remarks 5:00 pm
day: Day Two
Chair’s Opening Remarks 8:50 am
day: Day Two
Chair’s Closing Remarks 5:30 pm
day: Day One
PANEL DISCUSSION: Evaluating Advantages and Disadvantages of Different Administration Routes 12:30 pm
Delivery is a hot topic in the ophthalmology space. It’s clear that a myriad of factors influence which administration route is chosen, and it’s vital to choose the right one for your indication, taking into account what is best not just for effectiveness of the therapy, but for the patient. This panel discussion will bring…Read more
day: Day One
Discussing the Latest Advances in Sub-Retinal Administration of Gene Therapies 11:00 am
• Understanding the impact on patients of sub-retinal delivery • Exploring the latest technologies to increase effectiveness of sub-retinal delivery • Investigating the targets for which sub-retinal delivery is the optimal administration routeRead more
day: Day One